Friday 6 November 2026 Export BHVN’s income statement to Excel — free account

Biohaven Ltd.

BHVN Healthcare Biotechnology

EPS: +47.8%
Free cash flow: +26.6%
Total debt: −1.48%

Quarter to September 2026, against a year earlier

Revenue growth 5 yrs

14.23 0.33 +2.37%

Follow BHVN

Alert me

Market cap: $2.1B
P/E: 0.0×
Fwd P/E: −49.0×
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 14.88%

Capital & Financial Ratios $m

Size

Market Cap 2,100.00

Revenue ttm 995.42

Net income ttm (542.68)

Free cash flow ttm (473.18)

Net debt Q 103.17

Valuation

P/E 0.00

Forward P/E (49.00)

Price / sales 2.13

Forward P/S Powerpack

Price / FCF 0.00

Price / book 0.00

Financial health

Current ratio Q 3.05

Debt / equity Q (2.69)

Interest coverage Q (29.35)

Growth

Revenue growth Q +131.43%

Operating income growth Q +25.36%

EPS, this year +66.21%

EPS, next year A −0.50%

Revenue, next year A −100.00%

EPS, past 5 yrs —

EPS, next 5 yrs A +32.90%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 42.95%

10-year low 10-year high

EV/Sales against its own 10 years 46.63%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	382	486	319	161
Receivables	13	3	—	—
Inventory	—	—	—	—
Other	12	3	2	3
	442	538	368	192

	2023	2024	2025	Q'26
Payables	16	18	12	14
ST’ Debt	—	—	—	—
Other	—	85	—	—
	55	154	116	63

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	47.24%	0.00%	(54.11%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −0.80 Actual −0.86

−1.34 −1.08 −0.83 −0.58 −0.32

Q4 FY25 Beat +0.01

Q1 FY26 Miss −0.02

Q2 FY26 Miss −0.14

Q3 FY26 Miss −0.06

Q4 FY26 — Mar 1

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q4 FY25	−1.22	−1.21	Beat by 0.01
Q1 FY26	−0.86	−0.88	Miss by 0.02
Q2 FY26	−0.77	−0.91	Miss by 0.14
Q3 FY26	−0.80	−0.86	Miss by 0.06
Q4 FY26	−0.44	—	Reports 1 March 2027

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.88)	(0.91)	(0.86)	—	—
’25	(2.17)	(1.94)	(1.64)	(1.21)	(6.86)
’24	(2.20)	(3.64)	(1.70)	(1.85)	(9.28)
’23	(1.03)	(1.32)	(1.50)	(1.81)	(5.73)
’22	(2.97)	(6.21)	(1.75)	(3.32)	(12.75)
’21	(4.21)	(3.23)	(1.38)	(3.01)	(5.43)
’20	(3.07)	(3.08)	(3.27)	(3.62)	(3.01)

Fiscal quarters ending in the months shown.

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(150)	(85)	(107)	—	—
’25	(165)	(168)	(146)	(131)	(609)
’24	(103)	(168)	(141)	(171)	(582)
’23	(78)	(44)	(95)	(115)	(332)
’22	(59)	(68)	(96)	(75)	(298)
’21	(206)	(227)	320	(33)	(146)
’20	(151)	(176)	(164)	415	(76)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(150)	(86)	(107)	—	—
’25	(166)	(168)	(146)	(131)	(610)
’24	(103)	(171)	(142)	(170)	(586)
’23	(78)	(45)	(96)	(115)	(335)
’22	(59)	(89)	(100)	(76)	(304)
’21	(207)	(228)	321	(33)	(147)
’20	(174)	(177)	(184)	415	(120)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Sep ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—	995		—	94	71	125	+15.0%
	Gross margin, %	0.00	0.00	0.00	0.00	(0.11)	(0.30)	0.00	—	—	—	0.00		0.0 pt	Powerpack Biohaven Ltd.’s next three years, line by line See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(63)	(126)	(240)	(528)	(119)	(212)	(570)	(410)	(846)	(737)	(542)		+31.3%
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		0.0 pt
	Net income	(64)	(127)	(241)	(529)	(119)	(214)	(570)	(408)	(846)	(739)	(543)		+31.3%
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		n/m
	Earnings	(5.04)	(5.00)	(6.15)	(10.91)	(3.01)	(5.43)	(12.75)	(5.73)	(9.28)	(6.86)	(3.86)		+3.5%
	Cash flow	(2.34)	(3.40)	(5.03)	(7.78)	(1.93)	(3.70)	(6.65)	(4.66)	(6.38)	(5.66)	(3.13)		+10.3%
	Capex	0.00	(0.02)	(0.11)	(0.08)	(1.12)	(0.02)	(0.14)	(0.04)	(0.04)	(0.01)	0.00		+13.6%
	Free cash flow	(2.34)	(3.42)	(5.14)	(7.86)	(3.05)	(3.73)	(6.79)	(4.70)	(6.42)	(5.67)	(3.13)		+10.3%
	Book value	(0.14)	4.74	3.85	(0.15)	(9.96)	0.88	12.04	6.01	4.64	0.48	(0.65)		n/m
	Shares, m	13	28	39	48	39	39	45	71	91	108	139		+26.9%
Valuation, ×
Valuation, ×	P/E	—	—	—	—	0.00	0.00	—	—	—	—	0.00		0.0
	P/S	—	—	—	—	53.04	9.07	—	—	—	—	2.13		31.1
	P/B	—	—	—	—	0.00	156.42	—	—	—	—	0.00		78.2
	EV/Sales	—	—	—	—	52.75	10.14	—	—	—	—	2.23		31.4
	EV/FCF	—	—	—	—	(27.93)	(36.22)	—	—	—	—	(4.51)		(32.1)
Cash, $m
Cash, $m	Operating cash flow	(30)	(95)	(197)	(377)	(76)	(146)	(298)	(332)	(582)	(609)	(473)		+40.0%
	Capex	0	(1)	(4)	(4)	(44)	(1)	(6)	(3)	(4)	(1)	(1)		+44.5%
	Free cash flow	(30)	(95)	(201)	(381)	(120)	(147)	(304)	(335)	(586)	(610)	(473)		+40.0%
Balance, $m
Balance, $m	Working capital	16	127	253	262	326	53	497	387	384	252	129		+35.8%
	Net debt	(23)	(131)	(146)	(69)	(88)	(73)	(470)	(382)	(486)	(80)	103		+14.9%
	Shareholders’ equity	(2)	132	151	(7)	(392)	35	539	428	423	52	(98)		n/m
Returns, %
Returns, %	ROA	(440.53)	(160.08)	(110.29)	(166.74)	(23.01)	(51.58)	(141.89)	(69.48)	(150.03)	(138.54)	(161.32)		+302.0 pt
	ROIC	0.00	(13,367.54)	(3,004.63)	0.00	0.00	0.00	(515.93)	(590.46)	0.00	0.00	(6,659.91)		0.0 pt
	ROE	289.80	(320.22)	(170.33)	(737.03)	59.39	119.61	(198.89)	(84.44)	(198.83)	(310.75)	940.46		(600.5) pt
People
People	Employees	12	42	63	647	825	928	202	239	256	274	—		+41.6%
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Latest quarter Jun 2021 · fundamentals updated 2 Nov 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ADMA ADMA Biologics Inc	$3.0B	16.7×	14.0×	+5.12% (above 0%: growing)	+46.67% (above 0%: growing)	+1,709.49% (above 0%: growing)	70.81%	48.02%	Compare
VCEL Vericel Corporation	$2.7B	77.8×	72.9×	+26.47% (above 0%: growing)	+180.00% (above 0%: growing)	−19.39% (below 0%: shrinking)	73.34%	14.27%	Compare
PVLA Palvella Therapeutics, Inc.	$2.3B	— (loss-making)	— (loss-making)	−99.09% (below 0%: shrinking)	n/m	−136.38% (below 0%: shrinking)	100.00%	0.00%	Compare
CLDX Celldex Therapeutics, Inc.	$2.2B	— (loss-making)	— (loss-making)	−96.83% (below 0%: shrinking)	n/m	−35.45% (below 0%: shrinking)	100.00%	(366,468.18%)	Compare
LKFT Lakefront Biotherapeutics - Sponsored ADR	$2.2B	— (loss-making)	— (loss-making)	−95.35% (below 0%: shrinking)	+198.85% (above 0%: growing)	+18.22% (above 0%: growing)	25.95%	(982.91%)	Compare
VERA Vera Therapeutics, Inc.	$2.2B	— (loss-making)	—	—	n/m	−82.47% (below 0%: shrinking)	0.00%	0.00%	Compare
AUPH Aurinia Pharmaceuticals Inc	$2.2B	6.8×	17.6×	+13.93% (above 0%: growing)	0.00%	+4.41% (above 0%: growing)	90.08%	40.74%	Compare
IMNM Immunome, Inc.	$2.1B	— (loss-making)	— (loss-making)	+69.84% (above 0%: growing)	n/m	−26.96% (below 0%: shrinking)	100.00%	0.00%	Compare
BHVN Biohaven Ltd.	$2.1B	— (loss-making)	— (loss-making)	+131.43% (above 0%: growing)	n/m	+26.55% (above 0%: growing)	0.00%	0.00%
Median of peers	$2.2B	16.7×	17.6×	+5.12%	+113.34%	−23.17%	81.71%	0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 13 March 2026

Chief executive’s pay

Year	Total pay	Actually paid	$100 invested
2025	13.50m	(3.87m)	166.00
2024	10.48m	9.85m	534.00
2023	6.82m	22.15m	611.00
2022	5.97m	9.97m	198.00

Ownership

Directors and executive officers, together 13.80% of Common Shares

Janus Henderson Group plc 11.20% of Common Shares

Suvretta Capital Management, LLC 6.80% of Common Shares

John Childs 6.70% of Common Shares

Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Biohaven Ltd. (BHVN) Latest News

5 Nov

Impact 3 · 7:30 AM · PR Newswire

Biohaven Drives New Research in Graves' Disease: Phase 3 Pivotal Trial with BHV-1300 Underway and Three Scientific Posters at the 2026 American Thyroid Association Annual (ATA) Meeting

29 Oct

Impact 4 · 4:02 PM · PR Newswire

Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results

Impact 4 · 8:55 AM · Zacks

Wall Street Analysts Believe Biohaven Ltd. (BHVN) Could Rally 43.49%: Here's is How to Trade

26 Oct

Impact 4 · 7:30 AM · PR Newswire

Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous Nephropathy

23 Oct

Impact 4 · 11:56 AM · MT Newswires

Biohaven Could Transform With Troriluzole's FDA Approval, RBC Says

Impact 4 · 7:18 AM · Simply Wall St.

Why Biohaven (BHVN) Is Up 25.0% And What's Next After FDA Review Acceptance

22 Oct

Impact 4 · 10:28 PM · Insider Monkey

Biohaven (BHVN) Soars 25% on FDA Drug Review, Price Target Upgrade

Impact 4 · 12:24 PM · biopharmadive.com

Biohaven’s previously rejected rare disease drug to get fresh FDA review

Impact 4 · 9:27 AM · Stocktwits

BHVN Stock Eyes Biggest Single-Day Gain In 4 Years After FDA Approval For Vyglxia

Impact 4 · 7:43 AM · Investing.com

Biohaven stock surges 25% on FDA acceptance of drug filing

9 Oct

Impact 4 · 5:00 AM · pharmaceutical-technology.com

Biohaven partners with Ono in $100m IgG degrader deal

Impact 4 · 5:00 AM · hospitalmanagement.net

Biohaven partners with Ono in $100m IgG degrader deal

8 Oct

Impact 4 · 4:00 AM · PR Newswire

Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease

Impact 3 · 2:18 AM · Simply Wall St.

Is Biohaven (BHVN) Quietly Recasting Its Oncology Strategy Through Deeper Ties With Regeneron?

29 Sep

Impact 3 · 5:07 AM · Simply Wall St.

Why Did Regeneron Pharmaceuticals (REGN) Stock Drop Today?

28 Sep

Impact 4 · 7:30 AM · PR Newswire

Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026

25 Sep

Impact 3 · 5:08 PM · Simply Wall St.

Has Biohaven (BHVN) Fallen Far Enough to Look Fully Priced?

18 Sep

Impact 3 · 11:12 AM

Xenon Stock Craters 30% on Drug Trial Setback. Its Failure Could Be This Biotech’s Gain.

Impact 3 · 8:48 AM

Xenon Stock Craters on Drug Trial Setback. Its Failure Could Be This Rival’s Gain.

11 Sep

Impact 4 · 7:17 AM · clinicaltrialsarena.com

Biohaven’s epilepsy drug hit with FDA clinical hold

10 Sep

Impact 4 · 2:14 PM

Biohaven Stock Is Sinking. Epilepsy Drug Trial Roadblock Is Only the Latest Blow.

Impact 4 · 10:10 AM · InvestorsHub

Biohaven Shares Fall 17% After FDA Places Partial Hold on BHV-7000 Trials

Impact 4 · 9:45 AM · Stocktwits

BHVN Stock Crashes 10% – Why Did FDA Put Biohaven’s Epilepsy Trial On Partial Hold?

Impact 4 · 9:36 AM

Biohaven Plummets, A Boon For Rival Xenon, On A Surprise Seizure Setback

Impact 4 · 8:13 AM · biopharmadive.com

FDA places partial hold on Biohaven’s epilepsy drug

3 Sep

Impact 4 · 7:59 AM

Biohaven (BHVN) Cashes In On Its Biggest Epilepsy Bet

28 Aug

Impact 4 · 3:32 AM · The Motley Fool

Why Biohaven Stock Was Rocking the Market This Week

27 Aug

Impact 4 · 10:40 AM · pharmaceutical-technology.com

SK inks $795m Biohaven epilepsy deal, entering potassium channel opener race

Impact 4 · 9:42 AM

BHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy Program

26 Aug

Impact 4 · 1:00 PM · Stocktwits

BHVN Stock On Track For Best Day In Over 2 Months After SK Biopharmaceuticals Licenses Epilepsy Drug: Retail Now Awaits Obesity Trial Readout

Biohaven Ltd.

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance

Biohaven Ltd. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 13 March 2026

Chief executive’s pay

Ownership

Biohaven Ltd. (BHVN) Latest News

5 Nov

29 Oct

26 Oct

23 Oct

22 Oct

9 Oct

8 Oct

29 Sep

28 Sep

25 Sep

18 Sep

11 Sep

10 Sep

3 Sep

28 Aug

27 Aug

26 Aug

BHVN metrics, ten years each

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance

Biohaven Ltd. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 13 March 2026

Chief executive’s pay

Ownership

Biohaven Ltd. (BHVN) Latest News

5 Nov

29 Oct

26 Oct

23 Oct

22 Oct

9 Oct

8 Oct

29 Sep

28 Sep

25 Sep

18 Sep

11 Sep

10 Sep

3 Sep

28 Aug

27 Aug

26 Aug

BHVN metrics, ten years each

Stockrow Weekly